Category Archives: Drug costs

On the Skyrocketing Costs
Of MS Drugs: A Patient Point of View

Tweet Last week, Daniel M. Hartung, PharmD, MPH, and coauthors, published an open-access article in Neurology on astronomical increases in disease-modifying drugs for multiple sclerosis (MS) –many developed decades ago. Notably, they report that first-generation drugs — now cost about … Continue reading

Posted in Drug costs | Tagged , , , , | Comments Off on On the Skyrocketing Costs
Of MS Drugs: A Patient Point of View

Delay of Generics Hurts Consumer,
Taxpayer Wallets, and Patient Health

Tweet   To insure patent extensions of high-priced, blockbuster drugs, brand-name drug companies frequently pay generic drug manufacturers to stay out of the market. It makes cheaper, more affordable generic unavailable for years. The strategy is referred to as “Pay … Continue reading

Posted in Drug costs | Tagged , , , , , , , | Comments Off on Delay of Generics Hurts Consumer,
Taxpayer Wallets, and Patient Health

Why Sanofi’s Zaltrap Deal Won’t Help Patients

Tweet I got excited when I read the New York Times story Nov. 9 (“Sanofi Halves Price of Cancer Drug Zaltrap After Sloan-Kettering Rejection)”. Zaltrap is an intravenous infusion drug for metastatic colorectal cancer. It is used for advanced cancer … Continue reading

Posted in Drug costs | Tagged , , , , , | 1 Comment

When the Pharmaceutical Benefit Manager
Won’t Let You Go On Vacation

Tweet I  leave for vacation in the morning and it was not music to my ears when I heard that the pharmaceutical benefit manager (PBM), the company that reviews your drug use for your health plan or employer, denied an … Continue reading

Posted in Drug costs, pharmaceutical benefit managers | Tagged , | Comments Off on When the Pharmaceutical Benefit Manager
Won’t Let You Go On Vacation

5 Reasons Why I Find This Year’s Allergy Season
Especially Aggravating

Tweet 1.    Allegra, the non-sedating antihistamine has gone over the counter, with nearly psychedelic purple boxes knocking me down when I go into my local drugstore. It has also skyrocketed in cost. That means people with allergies are paying far … Continue reading

Posted in allergies, cost shifting, Drug costs, OTC drugs | Tagged , , , | 2 Comments

On Disclosure, Transparency, and Firewalls: A Call for Uniform Standards

Tweet Since Patient POV was launched March 29, I have been struggling with how to deal with the issue of industry-supported patient advocacy groups. On Thursday, ProPublica released its paper: “Financial Ties Bind Medical Societies to Drug and Device Makers” … Continue reading

Posted in American Academy of Ophthalmology, Avastin, disclosure, Drug costs, firewalls, nonprofits, Parkinson's Disease Foundation, patient advocacy groups, transparency | Tagged , , , , | 9 Comments

What the Macular Degeneration Drug Trial Means

Tweet Age-related macular degeneration is a leading cause of vision loss and blindness. The advanced form of the disease affects 1.6 million people in the United States.  That’s why results from the first year of a two-year clinical trial that … Continue reading

Posted in Age-related macular degeneration, Avastin, Blindness, Drug costs, Outcomes, Vision | Tagged , , | 8 Comments